Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
allo-APZ2-EB for RDEB
NCT03529877Phase 2Completed
- Sponsor
- RHEACELL
- Start
- Feb 2019
- Primary completion
- Nov 2021
- Modality
- Stem Cell Therapies
- Countries
- 5
01
Overview
A Phase 2 trial of EBESANAR in Recessive Dystrophic Epidermolysis Bullosa (RDEB), sponsored by RHEACELL. Started Feb 2019; status: completed.
02
Drugs
EBESANAR
03
Conditions
Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Beyond the preview
Go deeper on NCT03529877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03529877.